Mercer Global Advisors
ANIK icon

Mercer Global Advisors’s Anika Therapeutics ANIK Stock Holding History

Mercer Global Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Buy
25,285
+7,689
+44% +$114K ﹤0.01% 2589
2026
Q1 		$255K Buy
17,596
+4,851
+38% +$56.3K ﹤0.01% 2595
2025
Q4 		$122K Buy
+12,745
New +$122K ﹤0.01% 2678

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Mercer Global Advisors's ANIK Position: Q2 2026 in Review

Mercer Global Advisors increased its Anika Therapeutics (ANIK) stake by 44% in Q2 2026, buying an estimated $114K and bringing the position to 25,285 shares worth $370K. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Mercer Global Advisors first reported a position in ANIK in Q4 2025 and has held it in 3 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Mercer Global Advisors held 25,285 shares of Anika Therapeutics worth $370K as of Q2 2026.
  • Mercer Global Advisors bought 7,689 Anika Therapeutics shares in Q2 2026, an estimated $114K.
  • Anika Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2589 holding.
  • Mercer Global Advisors first reported a position in Anika Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.